Stage iv lung cancer ajcc v8 Trials in Pittsburgh, United States
Conditions / Stage iv lung cancer ajcc v8 / Pittsburgh, United States
Clinical trials for Stage iv lung cancer ajcc v8 investigate a range of treatment strategies and patient populations.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | ACTIVE_NOT_RECRUITING | — |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | ACTIVE_NOT_RECRUITING | — |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | ACTIVE_NOT_RECRUITING | — |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05633602 | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | ACTIVE_NOT_RECRUITING | — |